MEDITOXIN®

MEDITOXIN® Performance Benefits for Clinical Use

MEDITOXIN® is engineered for clinicians who need reliable, reproducible outcomes across both aesthetic and therapeutic applications. Its performance profile makes it efficient to dose, easy to use, and broadly compatible with established protocols. Performance advantages:

• Comparable efficacy to OnabotulinumtoxinA in glabellar lines, blepharospasm, cerebral palsy–related spasticity, and post-stroke spasticity.
• Similar safety profile to reference toxin in all evaluated studies.
• Predictable onset: initial effects generally appear within 1–3 days, with peak at 1–2 weeks for cosmetic indications.
• Duration: typically ~3–4 months for glabellar lines.
• Non-inferior performance provides confidence when transitioning from alternative brands.

About MEDITOXIN®

MEDITOXIN® is supplied as a freeze-dried, lyophilized white powder in a clear vial. It is indicated for both aesthetic and therapeutic muscle modulation, with specific approved uses backed by controlled clinical trials. Indicated uses include:

• Benign essential blepharospasm in patients ≥18 years.
• Equinus foot deformity in pediatric cerebral palsy (≥2 years).
• Temporary improvement of moderate–severe glabellar wrinkles in adults aged 18–65.
• Upper limb spasticity associated with stroke (≥20 years).

MEDITOXIN® has undergone multicenter, double-blind, randomized controlled studies demonstrating efficacy equivalent to leading global neuromodulators.

Ideal MEDITOXIN® Use Cases and Patient Profiles

MEDITOXIN® is structured for professional environments that prioritize precision, predictable dosing, and multi-indication flexibility. It fits seamlessly into practices managing both aesthetic and neurological treatments. Well-suited for:

• Clinics seeking a cost-efficient alternative with validated equivalence to OnabotulinumtoxinA.
• Practices treating glabellar lines, where onset, peak, and duration match patient expectations.
• Neurological treatment centers addressing blepharospasm, pediatric spasticity, or post-stroke spasticity.
• Clinics that need wholesale quantities with consistent potency across units.

Patient profiles:

• Adults seeking reduction of dynamic glabellar wrinkles.
• Patients requiring focal muscle relaxation for medical indications.
• Pediatric cerebral palsy patients needing controlled dosing for equinus deformity.
• Post-stroke patients with upper-limb spasticity requiring targeted injections.

MEDITOXIN® Product Range

MEDITOXIN® is available in multiple vial sizes designed to match clinical workflows. All units contain the same active complex and stabilization profile. Available vial strengths:

• Meditoxin 100 U
• Meditoxin 200 U

Potency per vial: 100 U of Clostridium botulinum toxin type A complex. Excipients: 0.5 mg human serum albumin, 0.9 mg sodium chloride per vial. Benefits for clinics:

• Streamlined inventory control.
• Scalable ordering for high-volume practices.
• Easier cost optimization when purchasing wholesale.

MEDITOXIN® Core Ingredients and Their Roles

Each vial contains a precisely measured formulation to stabilize potency and support consistent clinical activity. Active ingredient:

• Clostridium botulinum toxin type A complex – 100 Units

Stabilizing excipients:

• Human serum albumin (0.5 mg) – protein stabilizer ensuring structural integrity.
• Sodium chloride (0.9 mg) – maintains isotonicity for injection.

Together, these ingredients support predictable neuromodulatory performance and stability during reconstitution.

MEDITOXIN® Injection Techniques and Application Guide

MEDITOXIN® reconstitution and dosing must follow indication-specific protocols to maintain accurate delivery and treatment durability. Guidance below reflects leaflet-verified technical instructions.

Blepharospasm

• Inject 1.25–2.5 U per site using a 27–30G needle.
• Injections target medial/lateral pre-tarsal orbicularis oculi.
• Effect appears in ~3 days, peaks 1–2 weeks, lasts ~3 months.
• Maximum cumulative dose: 200 U per 30 days.

Pediatric Cerebral Palsy (Equinus Foot Deformity)

• Inject into medial and lateral heads of gastrocnemius using a 26–30G needle.
• Recommended total dose:
  • Hemiplegia: 4 U/kg
  • Diplegia: 6 U/kg divided between legs
• Do not exceed 200 U per treatment.

Glabellar Lines

• Reconstitute to 100 U / 2.5 mL (4 U per 0.1 mL).
• Total dose: 20 U, injected across 5 sites (corrugators × 4, procerus × 1).
• Use a 30G needle; avoid the levator palpebrae region to prevent ptosis.
• Duration: ~3–4 months.

Upper Limb Spasticity (Post-Stroke)

• Dose depends on targeted muscle groups. Clinical trials used doses up to 360 U.
• Inject superficial muscles with 24–30G needles; deeper muscles may require longer needles.
• EMG or nerve stimulation guidance recommended.

Dilution Guidelines

Standard dilutions (0.9% sodium chloride):

• 1.0 mL → 10 U / 0.1 mL
• 2.0 mL → 5 U / 0.1 mL
• 4.0 mL → 2.5 U / 0.1 mL
• 8.0 mL → 1.25 U / 0.1 mL

Reconstituted product should be used within 24 hours and stored at 2–8°C.

MEDITOXIN® Storage, Shelf Life, and Handling

MEDITOXIN® stability ensures efficient inventory management. Storage parameters:

• Store freeze-dried vial at ≤ –5°C or 2–8°C.
• Use reconstituted product within 24 hours.
• Inspect solution to ensure clear, colorless, particle-free quality.

Shelf life: 36 months from manufacturing date.

MEDITOXIN® Side Effects: What to Monitor

Across all multicenter trials, MEDITOXIN® demonstrated adverse event rates comparable to OnabotulinumtoxinA. Most events were mild and aligned with class-expected reactions. Common treatment-related AEs:

• Eyelid ptosis (noted in blepharospasm and glabellar studies).
• Extraocular muscle disorders.
• Local injection-site reactions or mild muscle weakness depending on treatment region.

No statistically significant safety differences were reported between treatment groups in any indication.

How to Order MEDITOXIN® for Your Practice

If you’re looking to buy MEDITOXIN® wholesale through licensed professional distribution channels, contact Doctor Medica customer support. We can give you guidance.

Key Practitioner Questions About MEDITOXIN® Answered

Is MEDITOXIN® proven comparable to OnabotulinumtoxinA? Yes. All Phase III randomized controlled trials showed non-inferior efficacy and similar safety. How long do results last? For glabellar indications, effects typically last 3–4 months. What dilution flexibility exists? The product supports dilution from 1.0 mL to 8.0 mL, allowing dose control from 10 U to 1.25 U per 0.1 mL. How quickly does it take effect? Initial improvement appears within 1–3 days depending on the indication. Is MEDITOXIN® suitable for high-volume practices? Yes—vial flexibility (50/100/200 U), wholesale availability, and stable shelf life support scalable usage.